Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: A 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study‡
References (29)
Biological actions and therapeutic potential of the glucagon-like peptides
Gastroenterology
(2002)What do we know about the secretion and degradation of incretin hormones?
Regal Pept
(2005)- et al.
Glucagon-like peptide 1 and inhibitors of dipeptidyl peptidase IV in the treatment of type 2 diabetes mellitus
Curr Opin Pharmacol
(2004) - et al.
Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: A double blind, randomized, placebo-controlled study in healthy male volunteers
Clin Ther
(2006) - et al.
Incretin hormones and insulin sensitivity
Trends Endocrinol Metab
(2005) - et al.
Role of incretin hormones in the regulation of insulin secretion in diabetic and nondiabetic humans
Am J Physiol Endocrinol Metab
(2004) Therapeutic strategies based on glucagon-like peptide 1
Diabetes
(2004)- et al.
Inhibitors ofdipeptidyl peptidase IV. A novel approach for the prevention and treatment of type 2 diabetes?
Expert Opin lnvestig Drugs
(2004) - et al.
GLPT receptor agonists and DPP-4 inhibitors in the treatment of type 2 diabetes
Norm Metab Res
(2004) - et al.
(2R)-4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine: A potent, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes
J Med Chem
(2005)
Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase-IV, in healthy subjects: Results from two randomized, double-blind, placebocontrolled studies with single oral doses
Clin Pharmacol Ther
(2005)
The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulindependent diabetes mellitus
N Engl J Med
(1993)
Effect of intensive blood-glucose control with met formin on complications in overweight patients with type 2 diabetes (UKPDS 34)
Lancet
(1998)
Cited by (0)
- ‡
Data in this paper were presented in abstract form at the 66th Scientific Sessions of the American Diabetes Association; June 9–13, 2006; Washington, DC.
- **
A list of the Sitagliptin Study 019 investigators appears in the Acknowledgments.
Copyright © 2006 Published by Elsevier Inc.